September 15, 2015
Beijing’s Yabao Pharmaceutical announced September 15 it is partnering with Primary Peptides, a UBC spinoff, to bring the Vancouver company’s medication across the Pacific. For years, the founders of Primary Peptides have been investing “considerable funds” to develop a treatment for stroke patients, according toMax Cynader, the former head of the University of British Columbia’s (UBC) Centre for Brain Health. Primary Peptides anticipates as much as $40 million investment from the Chinese pharmaceutical company for clinical trials.
Primary Peptides isn’t the only Vancouver-based life sciences company entering into licensing agreements with Chinese firms. In late August, another Vancouver company, Cardiome Pharma Corp. (TSX:COM) announced it would license a cardiovascular medication to China’s Eddingpharm after signing a similar agreement a year prior for another medication.
Click here for full article.